Spyre Therapeutics Stock Price, News & Analysis

Spyre Therapeutics (NASDAQ: SYRE) announced on Oct 3, 2025 that its independent Compensation Committee approved inducement stock option awards to three non-executive employees under the 2018 Equity Inducement Plan.

The awards, approved on Oct 1, 2025, total 42,500 options with a 10-year term and an exercise price of $16.46—the Nasdaq closing price on Oct 1, 2025. Options vest 25% on the first anniversary of each employee’s start date and then monthly at 1/48th thereafter, subject to continued service, and remain subject to the terms of the 2018 Plan.

Spyre Therapeutics (NASDAQ: SYRE) has initiated dosing in its Phase 2 SKYWAY basket trial for SPY072, their pioneering anti-TL1A antibody targeting rheumatic diseases. The trial focuses on treating patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).

SPY072 is designed for superior potency and convenience, with potential for quarterly or twice-yearly subcutaneous maintenance dosing. The SKYWAY trial, alongside the SKYLINE study, is expected to provide 9 proof-of-concept readouts in 2026-27. The company targets commercial markets exceeding $60B in annual revenue, with topline data expected in 2026.

Spyre Therapeutics announced positive interim Phase 1 results for its anti-TL1A antibody programs SPY002 and SPY072, demonstrating favorable safety profiles and extended half-life supporting quarterly dosing. Both antibodies showed ~75-day half-life, over 3x longer than first-generation alternatives, with complete TL1A suppression through 20 weeks. The company initiated SKYLINE-UC platform trial in May 2025 for ulcerative colitis and announced SKYWAY-RD basket trial for rheumatologic conditions starting Q3 2025. With $60B+ market potential and cash runway into 2028, Spyre expects 9 Phase 2 readouts over next two years, including monotherapy and combination therapy data from SKYLINE-UC in 2026-2027, and results from SKYWAY-RD trial testing SPY072 in RA, PsA, and axSpA in 2026.

Spyre Therapeutics (NASDAQ: SYRE) has scheduled a conference call and webcast for June 17, 2025, at 8:00am ET to discuss interim results from Phase 1 healthy volunteer trials of their SPY002 program. The program focuses on novel half-life extended anti-TL1A antibodies for treating Inflammatory Bowel Disease (IBD) and other immune-mediated diseases. The presentation will be accessible through the company's Investor Relations webpage, with an archived version available for a limited time at https://ir.spyre.com/events-and-presentations.

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on antibody engineering for IBD and immune-mediated diseases treatment, has granted inducement stock options to three non-executive employees. The grants, approved on June 2, 2025, include options to purchase 50,200 shares of common stock at an exercise price of $15.40 per share, matching Spyre's closing price on the approval date. These 10-year term options will vest 25% after one year of employment, followed by monthly vesting of 1/48th of shares, contingent on continued employment. The awards were granted under Spyre's 2018 Equity Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on developing antibody treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two major healthcare investor conferences in June 2025.

The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10am ET, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20am ET. Live webcasts and replays will be accessible through Spyre's investor relations website.

Spyre Therapeutics (NASDAQ:SYRE) reported Q1 2025 financial results and provided updates on its clinical pipeline. The company has $565 million in cash, providing runway into H2 2028. Key developments include: Pipeline Progress: - SPY001 (α4β7 antibody): Extended Phase 1 data shows good tolerability and potential for quarterly/biannual dosing - SPY002 (TL1A antibodies): Interim Phase 1 data expected this quarter; planned Phase 2 trials in UC and RA - SPY003 (IL-23 antibody): First participant dosed in Phase 1 trial Financial Results: - R&D expenses: $41.6M (Q1 2025) vs $34.9M (Q1 2024) - Net loss: $44.8M (Q1 2025) vs $43.9M (Q1 2024) The company plans to initiate Phase 2 studies mid-2025 in ulcerative colitis and rheumatoid arthritis, targeting markets worth approximately $50B annually, with 7+ proof-of-concept readouts expected in 2026-2027.

Spyre Therapeutics (NASDAQ: SYRE) presented promising data from its ongoing Phase 1 trial of SPY001, a novel half-life extended α4β7 antibody for Inflammatory Bowel Disease (IBD) treatment, at Digestive Disease Week 2025. The trial results showed SPY001 is well-tolerated with a half-life more than three times longer than vedolizumab. A single dose demonstrated rapid and sustained α4β7 receptor saturation at expected Phase 2 trough concentrations.

The company remains on schedule to launch its platform Phase 2 trial in mid-2025, testing SPY001 as both monotherapy and in combination with SPY002 (TL1A) and SPY003 (IL-23). Initial monotherapy data is expected in 2026. Preclinical data also showed that combined inhibition of α4β7 integrin and TL1A cytokine demonstrated superior results compared to monotherapy in mouse colitis models.

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on antibody engineering for IBD and immune-mediated diseases treatment, has announced equity inducement awards. The company's Compensation Committee approved stock options to purchase 64,400 shares of common stock for seven non-executive employees under the 2018 Equity Inducement Plan.

The stock options come with a 10-year term and an exercise price of $14.66 per share, matching Spyre's closing price on May 1, 2025. The vesting schedule includes 25% after one year and the remaining vesting monthly over the following three years, subject to continued employment.